The companies will jointly offer services and equipment solutions for the development, high-volume manufacture, and launch of multiplexed in vitro diagnostics.
The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.
The partners will develop multiplex tests to detect human pathogens in 75 minutes on Grenier's PCR-based Genspeed Test System.
The partners will launch the alliance by developing a colorimetric reader system for multiplexed lateral flow microarrays.
The partners will combine the sciFlexarrayer with Anteo's reagents to improve the functionality and shelf-life of activated glass and polymer slides and other arrays.
QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.
NEW YORK (GenomeWeb) — Scienion and Genomica today announced the CE IVD marking and launch of their jointly developed multiplex molecular assay for sexually transmitted infections.
NEW YORK (GenomeWeb) – The Institute for Global Food Security, MBio Diagnostics, and Scienion today announced they will combine their technologies to create tools to monitor marine toxins.
NEW YORK (GenomeWeb) – The AIT Austrian Institute of Technology, BioVendor, and Scienion announced today a partnership to develop an in vitro diagnostic test for the early detection of colon cancer.
NEW YORK (GenomeWeb) – Scienion is hoping its participation in a unique research project will help raise awareness for a microarray-based test for water quality monitoring.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.